Vertex Pharmaceuticals Inc (VRTX) Financials
Key financial figures for Vertex Pharmaceuticals Inc (Q2 2026).
Vertex grew Q2 2026 total revenue 12% to $3.33 billion and raised full-year revenue guidance to $13.1-$13.2 billion, driven by ALYFTREK uptake, CASGEVY, and JOURNAVX. Total revenue increased 12% year over year to $3.33 billion, with U.S. revenue up 11% to $2.06 billion and ex-U.S. revenue up 14% to $1.28 billion. Cystic fibrosis franchise: ALYFTREK revenue grew to $573.6 million (from $156.8 million in Q2 2025) as patients continue transitioning from TRIKAFTA/KAFTRIO, which declined to $2,497.2 million (from $2,551.1 million); total CF product revenue still rose to $3,207.9 million. CASGEVY (sickle cell/beta thalassemia gene therapy) revenue reached $76.4 million, more than double Q2 2025's $30.4 million. On the outlook: Raised FY2026 total revenue guidance to $13.1 billion to $13.2 billion (from $12.95 billion to $13.1 billion previously); non-CF product revenue guidance of $500 million or more unchanged; guidance excludes the pending Crinetics Pharmaceuticals acquisition. Figures are for Q2 2026, as Vertex Pharmaceuticals Incorporated reported them.
- Revenue
- $3.3B
- Net Income
- $1.1B
- EPS
- $4.34
- Total Assets
- $27.4B
- Operating Cash Flow
- $1.1B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $3.3B | $1.1B | $4.31 | 37.41% | $1.0B |
| Q1 FY2026 | $3.0B | $1.0B | $4.02 | 38.1% | $1.3B |
| Q4 FY2025 | $3.2B | $1.2B | $4.65 | 40.3% | $349M |
| Q3 FY2025 | $3.1B | $1.1B | $4.20 | 38.56% | $1.1B |
| Q2 FY2025 | $3.0B | $1.0B | $3.99 | 38.83% | $927M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $12.1B | $4.0B | $15.32 | 39.43% | $3.2B |
| FY2024 | $11.0B | -$536M | -$2.08 | -2.11% | -$790M |
| FY2023 | $9.9B | $3.6B | $13.89 | 38.83% | $3.3B |
Frequently asked questions
What was Vertex Pharmaceuticals Incorporated's revenue last quarter?
Vertex Pharmaceuticals Incorporated reported revenue of $3.33 billion for Q2 FY2026, up 12.5% from the same period a year earlier.
Is Vertex Pharmaceuticals Incorporated profitable?
Yes. Vertex Pharmaceuticals Incorporated reported net income of $1.10 billion for Q2 FY2026, a net margin of 32.99% on revenue.
How has Vertex Pharmaceuticals Incorporated's margin trended?
Operating margin was 37.41% in Q2 FY2026, compared with 38.83% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Vertex Pharmaceuticals Incorporated generate?
Vertex Pharmaceuticals Incorporated generated free cash flow of $1.01 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Vertex Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.